Clarifying costs and benefits of respiratory syncytial virus immunoprophylaxis

Pediatrics. 2014 Apr;133(4):e1101. doi: 10.1542/peds.2014-0077A.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Antiviral Agents / administration & dosage*
  • Female
  • Humans
  • Infant, Premature*
  • Male
  • Respiratory Sounds / drug effects*
  • Respiratory Syncytial Virus Infections / prevention & control*
  • Respiratory Syncytial Viruses / drug effects*

Substances

  • Antibodies, Monoclonal, Humanized
  • Antiviral Agents